Squarepoint
MNPR icon

Squarepoint’s Monopar Therapeutics MNPR Stock Holding History

Squarepoint’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$616K Buy
+7,738
New +$830K ﹤0.01% 3212
2026
Q2 		– Sell
-21,754
Closed -$1.19M – 4759
2026
Q1 		$1.19M Buy
21,754
+11,233
+107% +$679K ﹤0.01% 2623
2025
Q4 		$687K Buy
+10,521
New +$860K ﹤0.01% 2934

Other funds holding MNPR

SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Squarepoint's MNPR Position: Q3 2026 in Review

Squarepoint opened a new position in Monopar Therapeutics (MNPR) in Q3 2026: 7,738 shares worth $616K. The stake represents ﹤0.01% of the portfolio and ranks #3212 among its holdings. This is a return to the name: Squarepoint previously reported a position in MNPR as recently as Q1 2026.

Squarepoint first reported a position in MNPR in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.19M in Q1 2026. 43 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.

  • Squarepoint held 7,738 shares of Monopar Therapeutics worth $616K as of Q3 2026.
  • Monopar Therapeutics was a new Squarepoint position in Q3 2026.
  • Monopar Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #3212 holding.
  • Squarepoint first reported a position in Monopar Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Squarepoint's Monopar Therapeutics position peaked at $1.19M in Q1 2026.
  • 43 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.